title: [Prevalence and clinical significance of antiphospholipid antibodies in chronic hepatitis C].
abstract: BACKGROUND
  To know the prevalence of antiphospholipid antibodies in chronic hepatitis C and their relationship with disease progression.
  
  
  METHODS
  One hundred and twenty-eight patients with chronic hepatitis C and 93 healthy controls were enrolled up. We determined platelets, ALT, gamma GT, RNAHCV in serum and liver and non-organ specific antibodies, grade and stage in liver biopsy, risk factors, duration of disease and alcohol intake were also included. Portal hypertension and liver function parameters were studied. Antiphospholipid antibodies (APA): lupus anticoagulant (LA) and anticardiolipin antibodies (ACA) (IgG and IgM) were measured by EIA. Anti-beta 2 glycoprotein I antibodies were also detected by EIA in ACA positive patients.
  
  
  RESULTS
  Thirty one out of 128 (25%; 95% CI: 17.8%-33.4%) showed positive antiphospholipid antibodies. Positive ACA-IgG was higher in patients than controls (22% vs 3.2%; p < 0.05), whereas, ACA-IgM was similar (5% vs 3.2%; p = NS), and LA was absent in both groups. ALT levels, viraemia, viral load in liver, platelets, or ANA titre were similar in patients with and without positive ACA-IgG. Risk factors, duration of disease or alcohol intake were not related yet. Patients with staging F1 showed positive ACA-IgG 4 of 44 (9%; 95% CI: 2.5%-21.7%), in staging F2 7 of 39 (18%; 95% CI: 7.5%-33.5%) and in staging F4 17 of 45 (38%; 95% CI: 23.8%-53.5%; p < 0.005). ACA-IgG was significantly related to portal hypertension, Child-Pugh stage and presence of cirrhosis complications. Anti-beta 2 glycoprotein I antibodies were detected in ten (43.5%; CI 95%: 23.2%-65.5%) out of 23 ACA positive patients.
  
  
  CONCLUSIONS
  ACA-IgG seems to be associated with chronic hepatitis C, and could play a potential role in fibrosis progression and liver disease in these patients.
authors.affiliation: Servicio de Digestivo, Hospital Universitario de Valme, Sevilla. mromerog@meditex.es
authors.forename: M
authors.initials: M
authors.lastname: Romero Gómez
authors.forename: D
authors.initials: D
authors.lastname: López Lacomba
authors.forename: E
authors.initials: E
authors.lastname: García-Díaz
authors.forename: A
authors.initials: A
authors.lastname: Guil
authors.forename: R
authors.initials: R
authors.lastname: Gutiérrez
authors.forename: M A
authors.initials: MA
authors.lastname: Otero
authors.forename: I
authors.initials: I
authors.lastname: Marchante
authors.forename: E
authors.initials: E
authors.lastname: Suárez García
authors.forename: M
authors.initials: M
authors.lastname: Castro Fernández
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000097:blood*; D018450:Disease Progression; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood*; D006801:Humans; D008297:Male; D015995:Prevalence; D011379:Prognosis; D016036:Seroepidemiologic Studies
chemical_list: D017152:Antibodies, Antiphospholipid